

Preferred Mavyret for Hepatitis C Infection Treatment and Change to Quantity Limit for Hepatitis CM

Dear Member,

On January 1, 2023, the Texas Health and Human Services Commission (HHSC) selected one medication, Mavyret, as the primary drug choice for treating Hepatitis C infection. This medication works toward significantly reducing chronic Hepatitis C.

Quantity Limit Change

HHSC is working to improve access and medication adherence by allowing your doctors to write prescriptions for entire courses of treatment for Hepatitis C.

What does this mean to me as a member?

This means that your doctor can write your prescriptions for an entire treatment cycle, and you will not have to request additional refills during your treatment period. However, your doctor can decide to have you return for further testing if it is needed.

Reminder

All Medicaid members are eligible for DAA treatment with the preferred drug choice regardless of your METAVIR fibrosis score, and prior authorization is not required. The table below shows the national drug codes (NDCs) impacted by this change:

Drug Name	NDC	Jan 1, 2023 PDL status
Mavyret	00074260028 00074262528	Preferred
Epclusa	61958220101 61958220301 61958220401 61958220402 61958220501 61958220502	Non-Preferred
Vosevi	61958240101	Non-Preferred

If you have any questions, call Member Services at (866) 449-6848/(877) 319-6826 - CHIP RSA, Monday-Friday, 8 a.m.- 6 p.m., central time or 7-1-1 (hearing impaired).